English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Advertisement
    Remove Ad
    HomeNewsBusinessmoneycontrol ResearchCipla — While COVID scope continues, watch out for FY23 !!!

    Cipla — While COVID scope continues, watch out for FY23 !!!

    Just when it seemed that Covid tailwinds are waning for Cipla, the drug maker has repositioned itself for the opportunities emerging from the second wave of the pandemic

    June 16, 2021 / 17:11 IST
    French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo - RTX2FAUX
    • PRO Panorama

      Ideas For Profit | Fiem Industries: Can this auto ancillary stock gain despite industry challenges?

      Jun 14, 2022 / 08:38 PM IST

      Fiem Industries posted a strong set of numbers in Q4FY22, despite significant demand weakness in the two-wheeler industry and comm...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts

    Disclosure & Disclaimer

    This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More